<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180712040438N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-12</date_registration>
      <primary_sponsor>Kermanshah University of Medical Sciences</primary_sponsor>
      <public_title>The effect of dietary approaches to stop hypertension (DASH) diet on obesity</public_title>
      <acronym>DASHLOW</acronym>
      <scientific_title>Comparison of the effect of dietary approaches to stop hypertension (DASH) diet with regular hypocaloric diet on on anthropometric indices, expression of some micro RNAs and genes involved in metabolic, inflammatory and hormonal status in obese adults</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-07-25</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/49332</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Permuted block randomization method: First, the list of participants was provided according to their referral. Then all possible sequences that can be written with three groups, were written on paper (for 3 groups 12 sequences can be written). Then one of the numbers from 1 to 12 was considered for each sequence, for example for the ABC sequence 1 and for the ACB sequence 2 and as such, one of the numbers 3 to 6 was considered for the other 4 sequences. Then, using random number table, the random numbers were selected from one point to the left or right. Wherever the random number was 1 to 6, the corresponding sequence was recorded on the paper. This method continued until groups for the total number of participants were determined. Then, the names of subjects on the list were allocated to the specific groups according to the sequence of groups which had been determined by the above mentioned procedure, Blinding description: Participants, care giver and investigator are unaware of the differences in the incoming regimes.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Obesity.</hc_freetext>
      <i_freetext>Intervention 1: Control group: They will use a diet based on the Iranian food pyramid and routine training that is normally provided by hospital nutrition experts. Intervention 2: Intervention group: Receiving hypocaloric diet. In this group, the required energy of each person will be determined based on Mifflin-St Jeor formula, the rate of 500 kcal will be deducted then units of each food groups will be determined based on a regular diet. Intervention 3: Intervention group: Receiving dietary approaches to stop hypertension diet (DASH) hypocaloric diet. In this group, the required energy of each person will be determined based on Harris Benedict formula, the rate of 500 kcal will be deducted then units of each food groups will be determined based on DASH diet.DASH diet is rich in fruits, vegetables, whole grains, low-fat dairy foods and is limited in saturated fatty acids, total fat and cholesterol, refined cereals and sugar sweetened drinks with an overall 2400 mg per day sodium intake.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data collected for the primary outcomes will be shared

When:
Accessibility to data is possible 8 months after publication.

To whom:
The data will only be available for people working in academic institutions.

Conditions:
he data of the present study will only be accessible by other researchers, for conducting Meta analysis

Where to obtain:
Dr Jalal Moludi, Faculty of Nutrition Sciences and Food Technology, Kermanshah University of Medical Sciences, +989399516766, j.moloudi@yahoo.com

How to obtain:
Any one who request our data should provide a brief explanation of the purpose and method of their meta-analysis study. The applicant's request will be reviewed by the researchers and if all agree, the requested data will be sent to the applicant via email in the form of an Excel file. All these steps will not take more than 10 days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Jalal Moludi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isar St</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1236549875</zip>
        <telephone>+98 41 3335 2148</telephone>
        <email>moludij@tbzmed.ac.ir</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Jalal Moludi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isar St</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>32164547965</zip>
        <telephone>+98 41 3335 2148</telephone>
        <email>moludij@tbzmed.ac.ir</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Body mass index 35-25 kg /m 2 
Age range from 20 to 50 years old</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with severe diseases
 Pregnancy
 Alcohol consumption</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E66</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Overweight and obesity</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: They will use a diet based on the Iranian food pyramid and routine training that is normally provided by hospital nutrition experts.</i_keyword>
      <i_keyword>Intervention group: Receiving hypocaloric diet. In this group, the required energy of each person will be determined based on Mifflin-St Jeor formula, the rate of 500 kcal will be deducted then units of each food groups will be determined based on a regular diet.</i_keyword>
      <i_keyword>Intervention group: Receiving dietary approaches to stop hypertension diet (DASH) hypocaloric diet. In this group, the required energy of each person will be determined based on Harris Benedict formula, the rate of 500 kcal will be deducted then units of each food groups will be determined based on DASH diet.DASH diet is rich in fruits, vegetables, whole grains, low-fat dairy foods and is limited in saturated fatty acids, total fat and cholesterol, refined cereals and sugar sweetened drinks with an overall 2400 mg per day sodium intake.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anthropometric indices. Timepoint: Baseline and End-of-trial. Method of measurement: Digital scale.</prim_outcome>
      <prim_outcome>Blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Automatic clinical chemical analysis device.</prim_outcome>
      <prim_outcome>Lipid profile including TG, HDL-C,  and TC. Timepoint: Baseline and End-of-trial. Method of measurement: Automatic clinical chemical analysis device.</prim_outcome>
      <prim_outcome>Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Insulin.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Adipokines levels include spixin, leptin, and adiponectin. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.</sec_outcome>
      <sec_outcome>Interleukin 6 and 10. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.</sec_outcome>
      <sec_outcome>Hs-CRP. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.</sec_outcome>
      <sec_outcome>Expression of micro RNA  122a, mir15, mir155a, mir 146, mir 193. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: RT-PCR.</sec_outcome>
      <sec_outcome>PPARg Expression. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: RT-PCR.</sec_outcome>
      <sec_outcome>FTO Expression. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: RT-PCR.</sec_outcome>
      <sec_outcome>Bile acid (BA) profiles. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Elisa.</sec_outcome>
      <sec_outcome>LPS. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.</sec_outcome>
      <sec_outcome>Trimethylamine N-oxide. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kermanshah University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-06-16</approval_date>
        <contact_name>Ethics Committee of Kermanshah University of Medical Sciences</contact_name>
        <contact_address>Faculty of Nutrition and Food Technology, Next to Farabi Hospital, Kermanshah, Iran , Postcode: 6719851552 Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
